Protara Therapeutics
TARA
38 hedge funds and large institutions have $22.2M invested in Protara Therapeutics in 2024 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 14 increasing their positions, 7 reducing their positions, and 7 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 7
73% more call options, than puts
Call options by funds: $52K | Put options by funds: $30K
57% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 7
21% more capital invested
Capital invested by funds: $18.3M → $22.2M (+$3.89M)
12% more funds holding
Funds holding: 34 → 38 (+4)
10.76% more ownership
Funds ownership: 39.99% → 50.75% (+11%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$5.56M |
| 2 |
SC
Stempoint Capital
New York
|
+$2.38M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$1.87M |
| 4 |
BC
Boxer Capital
San Diego,
California
|
+$1.76M |
| 5 |
AC
Armistice Capital
New York
|
+$1.52M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$1.14M |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$102K |
| 3 |
TSS
Two Sigma Securities
New York
|
-$69.7K |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
-$64.3K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
-$52.2K |
TARA Hedge Fund Activity: Q2 2024 in Review
38 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Protara Therapeutics (TARA) for Q2 2024, worth a combined $22.2M — up 21% from $18.3M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new TARA positions and 7 closed out — a net gain of 4 holders — while 14 added to existing stakes and 7 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $5.56M. The largest seller was Opaleye Management, cutting an estimated $1.14M.
- 38 institutional investors held Protara Therapeutics (TARA) as of Q2 2024, up from 34 in Q1 2024.
- Funds reported $22.2M of Protara Therapeutics stock for Q2 2024, up 21% quarter-over-quarter.
- 11 funds opened new Protara Therapeutics positions in Q2 2024 and 7 closed out, a net change of +4 holders.
- The largest Protara Therapeutics buyer in Q2 2024 was RA Capital Management, an estimated $5.56M added.
- The largest Protara Therapeutics seller in Q2 2024 was Opaleye Management, an estimated $1.14M sold.
Based on aggregated 13F filings for Q2 2024.